₹69.90
+9.18%NSE close, 16 Nov 2026
−34.12%
Brooks Laboratories is a small cap company, listed on NSE under the symbol BROOKS. At ₹69.90 a share, the market values the whole company at ₹206 crore.
In FY26, it reported sales of ₹86 crore and a net profit of ₹25 crore, an operating margin of 8.2%. Over the last three years, sales grew 10.8% a year.
The market values the company at 2.8 times its profit over the last twelve months and 1.09 times its book value; its return on equity is 38.6% and it has almost no borrowings.
Promoters hold 52.62% of the shares. Foreign institutions hold 0.04%, and domestic institutions, mutual funds among them, 10.50%.
Over the past year the share price has fallen 33.6%, and it is 37.8% below its 52-week high.
₹ crore. Consolidated figures.
The financial results for the quarter and half year ended September 30, 2026.
Outcome of Board Meeting held on October 14, 2026.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 21.8 | 17.7 | 17.9 | 20.8 | 20.5 | 23.3 | 25.5 | 23.5 | 16.6 | 20.2 | 23.0 | 19.3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 20.7 | 17.3 | 17.7 | 19.3 | 18.9 | 21.8 | 22.4 | 20.9 | 15.8 | 19.5 | 21.1 | 18.9 |
| Operating profit | 1.1 | 0.4 | 0.3 | 1.5 | 1.6 | 1.5 | 3.1 | 2.5 | 0.7 | 0.7 | 1.9 | 0.3 |
| Operating margin | 5.1% | 2.1% | 1.6% | 7.3% | 7.7% | 6.6% | 12.3% | 10.7% | 4.4% | 3.4% | 8.1% | 1.7% |
| Other income | 0.2 | 0.7 | 0.1 | 0.2 | 0.0 | 0.6 | 0.2 | 0.4 | 0.1 | 0.4 | 0.2 | 1.0 |
| Interest | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | 0.2 | 0.3 |
| Depreciation | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 |
| Profit before tax | 0.6 | 0.3 | −0.2 | 1.0 | 0.9 | 1.5 | 2.7 | 2.2 | 0.3 | 0.6 | 1.4 | 75.3 |
| Tax | 0.0 | 0 | 0 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 | 5.3 |
| Net profit | −3.9 | −9.6 | −2.4 | −4.0 | −2.1 | −1.5 | 9.6 | 8.0 | 5.5 | 1.5 | −1.8 | 67.6 |
| EPS (₹) | -1.51 | -3.77 | -0.94 | -1.51 | -0.82 | -0.54 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 | 22.95 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 S | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 55.0 | 69.7 | 77.3 | 91.1 | 63.1 | 79.5 | 82.6 | 85.7 |
| Expenses | 63.4 | 73.6 | 76.7 | 105 | 89.6 | 76.3 | 77.6 | 78.7 |
| Operating profit | −8.4 | −3.9 | 0.5 | −14.4 | −26.5 | 3.2 | 4.9 | 7.1 |
| Operating margin | -15.2% | -5.6% | 0.7% | -15.8% | -42.0% | 4.1% | 6.0% | 8.2% |
| Other income | 2.9 | 0.4 | 0.7 | 0.9 | 0.3 | 1.0 | 0.9 | 1.2 |
| Interest | 3.0 | 3.4 | 3.1 | 3.1 | 2.2 | 0.8 | 1.0 | 0.8 |
| Depreciation | 6.5 | 6.7 | 7.1 | 7.4 | 7.0 | 1.8 | 1.6 | 1.6 |
| Profit before tax | −15.0 | −13.5 | −9.0 | −23.9 | −35.1 | 1.6 | 3.2 | 5.8 |
| Tax | −0.1 | 10.9 | 10.4 | −4.6 | −7.3 | 0.0 | 0.2 | 0 |
| Net profit | −14.8 | −24.4 | −19.4 | −16.2 | −27.9 | −19.6 | −10.0 | 24.6 |
| EPS (₹) | -9.20 | -13.84 | 6.31 | -7.82 | -10.76 | -7.67 | -3.72 | 8.35 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | −37.4 | 2.5 | 9.3 | −3.3 |
| From investing | −24.9 | −46.0 | −2.9 | −0.3 |
| From financing | 64.1 | 43.4 | 0.2 | −2.2 |
| Spent on fixed assets | −27.6 | −0.9 | −3.5 | −2.7 |
| Free cash flow | −65.1 | 1.6 | 5.8 | −6.1 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | -26.9% | -35.0% | -25.1% | -17.8% | -44.1% | -24.7% | -12.1% | 28.6% |
| Operating margin | -15.2% | -5.6% | 0.7% | -15.8% | -42.0% | 4.1% | 6.0% | 8.2% |
| Return on equity | – | – | – | – | -37.7% | -29.9% | -10.2% | 20.0% |
| Return on capital employed | – | – | – | – | -41.3% | 3.4% | 4.1% | 5.1% |
| Return on assets | – | – | – | – | -25.4% | -21.7% | -8.1% | 16.6% |
| Debt to equity | – | – | – | – | 0.08 | 0.08 | 0.06 | 0.06 |
| Interest coverage | -4.10 | -3.00 | -1.90 | -6.70 | -15.10 | 2.80 | 4.10 | 7.90 |
| Debt to assets | – | – | – | – | 0.05 | 0.06 | 0.05 | 0.05 |
| Current ratio | – | – | – | – | 0.84 | 1.35 | 1.48 | 1.72 |
| Quick ratio | – | – | – | – | 0.49 | 0.93 | 1.08 | 1.21 |
| Cash ratio | – | – | – | – | 0.00 | 0.01 | 0.00 | 0.30 |
| Asset turnover | – | – | – | – | 0.58 | 0.88 | 0.67 | 0.58 |
| Fixed asset turnover | – | – | – | – | 4.50 | 6.08 | 6.60 | 6.39 |
| Inventory turnover | – | – | – | – | – | 5.90 | 5.90 | 4.60 |
| Receivables turnover | – | – | – | – | 4.90 | 4.90 | 4.10 | 5.30 |
| Gross margin | – | – | – | – | – | 28.8% | 34.5% | 40.5% |
| Cash from operations to profit | – | – | – | – | – | – | – | 38.0% |
| Effective tax rate | – | – | – | – | – | 1.9% | 5.6% | 0.0% |
Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Resignation of Ms Krutika Rane as Company Secretary and Compliance Officer of the Company w.e.f. October 09, 2026.
A copy Srutinizers report of Annual General Meeting held on September 03, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 03, 2026
Addendum to the Notice of 24th Annual General Meeting of the Company.
Intimation Of Record Date, E-Voting Dates And Book Closure Date
The financial results for the period ended Jun 30, 2026.
Letter to Shareholders - Annual Report for the FY 2025-26.
Notice of Annual General Meeting to be held on September 03, 2026